Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 17Recruiting 4Active not recruiting 4Terminated 3Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 2Genitourinary 2Thoracic 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 37Lung Neoplasms 27Triple Negative Breast Neoplasms 25Ovarian Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Fallopian Tube Neoplasms 16Small Cell Lung Carcinoma 15Neoplasm Metastasis 14Endometrial Neoplasms 13Esophageal Neoplasms 11Neoplasms 10Prostatic Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Carcinoma 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Oropharyngeal Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Laryngeal Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Stomach Neoplasms 4Mouth Neoplasms 4Melanoma 4Carcinoma, Ovarian Epithelial 4Urothelial Cancer 3

Interventions

Oxaliplatin 21pembrolizumab 17Capecitabine 15Nivolumab 13Paclitaxel 12Fluorouracil 12Leucovorin 11Docetaxel 10atezolizumab 7Trastuzumab 7tislelizumab 5Ramucirumab 5durvalumab 4Standard of Care 4Magnetic Resonance Spectroscopy 4Irinotecan 4Cisplatin 4Carboplatin 4zolbetuximab 3zimberelimab 3apatinib 3Specimen Handling 3S 1 (combination) 3Gemcitabine 3Bevacizumab 3trifluridine tipiracil drug combination 2tremelimumab 2trastuzumab deruxtecan 2relatlimab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Stomach Neoplasms × Carboplatin × Clear all
NCT03044613 2026-03-23

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
32 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02931890 2024-05-02

CRITICS-II

The Netherlands Cancer Institute

Phase 2 Active not recruiting
207 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡